[go: up one dir, main page]

DE69434286D1 - Immunologische bestimmungen von prostata-spezifischem antigen - Google Patents

Immunologische bestimmungen von prostata-spezifischem antigen

Info

Publication number
DE69434286D1
DE69434286D1 DE69434286T DE69434286T DE69434286D1 DE 69434286 D1 DE69434286 D1 DE 69434286D1 DE 69434286 T DE69434286 T DE 69434286T DE 69434286 T DE69434286 T DE 69434286T DE 69434286 D1 DE69434286 D1 DE 69434286D1
Authority
DE
Germany
Prior art keywords
psa
specific antigen
prostate
provisions
immunological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434286T
Other languages
English (en)
Other versions
DE69434286T2 (de
Inventor
L Dowell
A King
B Alexander
H Smith
B O'morchoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE69434286D1 publication Critical patent/DE69434286D1/de
Application granted granted Critical
Publication of DE69434286T2 publication Critical patent/DE69434286T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69434286T 1993-12-29 1994-12-22 Immunologische bestimmungen von prostata-spezifischem antigen Expired - Lifetime DE69434286T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/174,964 US5599677A (en) 1993-12-29 1993-12-29 Immunoassays for prostate specific antigen
PCT/US1994/014902 WO1995018381A1 (en) 1993-12-29 1994-12-22 Immunoassays for prostate specific antigen
US174964 2002-06-19

Publications (2)

Publication Number Publication Date
DE69434286D1 true DE69434286D1 (de) 2005-04-07
DE69434286T2 DE69434286T2 (de) 2005-12-29

Family

ID=22638254

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434286T Expired - Lifetime DE69434286T2 (de) 1993-12-29 1994-12-22 Immunologische bestimmungen von prostata-spezifischem antigen

Country Status (8)

Country Link
US (2) US5599677A (de)
EP (1) EP0741868B1 (de)
JP (2) JP3486413B2 (de)
AT (1) ATE290212T1 (de)
AU (1) AU1518795A (de)
DE (1) DE69434286T2 (de)
ES (1) ES2238678T3 (de)
WO (1) WO1995018381A1 (de)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5723302A (en) * 1993-05-14 1998-03-03 Nordion International Inc. Detection of prostate-specific antigen in breast tumors
US5654161A (en) * 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
EP0789032A2 (de) * 1996-02-01 1997-08-13 Bayer Corporation Verfahren zur Herstellung eines monoklonalen Antikörpers, der zu einer equimolären Responz gegen eine freie und komplexierte Analyseprobe in einem monoklonalen/polyklonalen Sandwichimmuntest
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
AU720802B2 (en) 1996-07-03 2000-06-15 Millenium Pharmaceuticals, Inc. Detection of cancer by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
US5840501A (en) * 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
IL121659A (en) * 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5856182A (en) * 1996-11-18 1999-01-05 Beckman Coulter, Inc. Monoclonal antibodies specific for the PSA-ACT complex
US6548260B1 (en) * 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
US7288636B2 (en) * 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2290582C (en) * 1997-05-14 2005-08-02 Kenneth F. Buechler Rapid evaluation of the ratio of biological molecules
US6780598B1 (en) * 1997-06-13 2004-08-24 William J. Kokolus Method of identifying and locating immunobiologically-active linear peptides
CA2243033A1 (en) * 1997-07-31 1999-01-31 Bayer Corporation Determination of psa-act
US6194152B1 (en) 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
US6649420B1 (en) * 1997-08-26 2003-11-18 Thomas L. Cantor Methods and devices for detecting no-complexed prostate specific I antigen
US5994085A (en) * 1997-08-26 1999-11-30 Cantor; Thomas L. Methods and devices for detecting non-complexed prostate specific antigen
WO1999012553A1 (en) * 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
US6352834B1 (en) * 1998-07-17 2002-03-05 University Of Iowa Research Foundation Prostate cancer assays and related methods
EP1151142A2 (de) 1999-01-28 2001-11-07 Gen-Probe Incorporated Nukleinsäure sequenzen für den nachweis von genetischen markern für krebs in einer biologischen probe
JP4723725B2 (ja) 1999-04-20 2011-07-13 ターゲット ディスカバリー， インコーポレイテッド 代謝経路を分析するための方法
DE19957065B4 (de) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
DE60138465D1 (de) 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
ATE282205T1 (de) 2000-07-24 2004-11-15 Health Research Inc Verfahren zur detektion von prostata-spezifischem membran-antigen in serum
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6764825B1 (en) * 2000-10-13 2004-07-20 Tang J. Wang Methods and device for detecting prostate specific antigen (PSA)
US6727104B2 (en) 2001-02-05 2004-04-27 The Board Of Regents Of The University Of Nebraska Microcolumn chromatographic immunoassays
US6500671B2 (en) 2001-02-05 2002-12-31 The Board Of Regents Of The University Of Nebraska Loading microcolums for the separation of analytes from a sample in the millisecond time scale
US6720193B2 (en) * 2001-02-05 2004-04-13 Board Of Regents Of The University Of Nebraska Analysis of free analyte fractions by rapid affinity chromatography
CA2442993C (en) * 2001-04-10 2011-10-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
US20030007974A1 (en) * 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
AU2002305767B2 (en) * 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
EP1953244A1 (de) 2002-01-09 2008-08-06 Nakamura, Yusuke Krebsprofile
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US20040018577A1 (en) * 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
DK1563100T3 (da) * 2002-11-01 2013-08-05 Iris Int Inc Fortrængningssandwich-immuno-PCR
EP1581794B1 (de) * 2003-01-10 2008-09-17 Millennium Pharmaceuticals, Inc. Verfahren zur bestimmung des wiederauftretens von prostata krebs
US8003765B2 (en) * 2003-04-09 2011-08-23 Stony Brook Anaesthesiology, University Faculty Practice Corporation Methods, antibodies and kits for detecting cerebrospinal fluid in a sample
US20040203079A1 (en) * 2003-04-09 2004-10-14 Research Foundation Of The State University Of New York Methods and kits for detecting cerebrospinal fluid in a sample
US20070003992A1 (en) * 2003-04-09 2007-01-04 Pentyala Srinivas N Methods and kits for detecting cerebrospinal fluid in a sample
EP1639090A4 (de) 2003-06-09 2008-04-16 Univ Michigan Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20050266503A1 (en) * 2004-05-24 2005-12-01 Esoterix, Inc. Simultaneous assay of target and target-drug binding
US20060135455A1 (en) 2004-06-01 2006-06-22 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7279281B2 (en) * 2004-06-01 2007-10-09 The Regents Of The University Of Michigan Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
PT1815028E (pt) * 2004-11-03 2012-01-24 Iris Molecular Diagnostics Inc Microbolhas para separação por afinidade
US8338579B2 (en) 2004-11-03 2012-12-25 Iris Molecular Diagnostics, Inc. Homogeneous analyte detection
US7439024B2 (en) * 2005-06-01 2008-10-21 The United States Of America As Represented By The Department Of Veterans Affairs Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007133250A2 (en) 2005-10-31 2007-11-22 Austin Gurney Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
JP2009540333A (ja) 2006-06-12 2009-11-19 プレジデント アンド フェロウズ オブ ハーバード カレッジ ナノセンサーおよび関連技術
US20080100279A1 (en) * 2006-06-15 2008-05-01 University Of South Florida Nano-Based Device for Detection of Disease Biomarkers and Other Target Molecules
US8349604B2 (en) * 2006-06-15 2013-01-08 University Of South Florida Nano-based device for detection of disease biomarkers and other target molecules
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
US8575663B2 (en) 2006-11-22 2013-11-05 President And Fellows Of Harvard College High-sensitivity nanoscale wire sensors
US8148147B2 (en) * 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008137008A2 (en) 2007-05-04 2008-11-13 Claros Diagnostics, Inc. Fluidic connectors and microfluidic systems
EP2518507A1 (de) 2007-05-18 2012-10-31 Duke University Serum-Biomarker für den frühen Nachweis von Lungenkrebs
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
CA2691378A1 (en) 2007-07-02 2009-01-08 Oncomed Pharmaceuticals, Inc. Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer
WO2009021190A2 (en) * 2007-08-08 2009-02-12 Renovar, Inc. Systems and methods for characterizing lupus erythematosus
EP2201134B1 (de) * 2007-09-19 2018-11-21 The Research Foundation of State University of New York Genexpressionssignaturen in angereicherten tumorzellproben
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
CA2716027A1 (en) * 2008-02-21 2009-08-27 Iris International Inc. Method for early determination of recurrence after therapy for prostate cancer
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
CN102272599B (zh) 2008-11-11 2015-01-14 密执安大学评议会 抗cxcr1组合物和方法
US8362318B2 (en) * 2008-12-18 2013-01-29 Board Of Trustees Of Michigan State University Enzyme directed oil biosynthesis in microalgae
US20100173791A1 (en) 2009-01-05 2010-07-08 Bio-Rad Laboratories, Inc. Process design using mass spectrometry
DE202010018623U1 (de) 2009-02-02 2018-12-07 Opko Diagnostics, Llc Strukturen zur Steuerung der Lichtwechselwirkung mit mikrofluidischen Vorrichtungen
US8481698B2 (en) * 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
WO2010126670A2 (en) 2009-03-27 2010-11-04 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
US20100272824A1 (en) * 2009-04-16 2010-10-28 The Texas A&M University System Compositions and methods for preventing and monitoring disease
JP2013501919A (ja) * 2009-08-07 2013-01-17 アフィニマーク テクノロジーズ，インコーポレイテッド 脳脊髄液の免疫的識別のための装置および方法
US9056114B2 (en) 2009-08-28 2015-06-16 Jeffrey P. Erickson Chemical induction of lactation
US9297796B2 (en) 2009-09-24 2016-03-29 President And Fellows Of Harvard College Bent nanowires and related probing of species
WO2011082253A2 (en) 2009-12-30 2011-07-07 Board Of Trustees Of Michigan State University A method to produce acetyldiacylglycerols (ac-tags) by expression ofan acetyltransferase gene isolated from euonymus alatus (burning bush)
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US8574832B2 (en) 2010-02-03 2013-11-05 Massachusetts Institute Of Technology Methods for preparing sequencing libraries
WO2011116209A2 (en) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US9125931B2 (en) 2010-04-06 2015-09-08 Massachusetts Institute Of Technology Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
CN103168118A (zh) 2010-04-06 2013-06-19 麻省理工学院 用减少数量的转录物测量进行的基因表达概况分析
EP2583101B1 (de) * 2010-06-17 2015-09-16 Koninklijke Philips N.V. Multi-epitop-test
EP2407242A1 (de) 2010-07-13 2012-01-18 Dublin City University Direkte Klonanalyse und Auswahltechnologie
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
WO2013119923A1 (en) 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
KR101933752B1 (ko) 2012-03-05 2018-12-28 오와이 아크틱 파트너스 에이비 전립선 암의 위험성 및 전립선 부피를 예측하는 방법 및 장치
WO2014005076A2 (en) 2012-06-29 2014-01-03 The Regents Of The University Of Michigan Methods and biomarkers for detection of kidney disorders
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP3530284B1 (de) 2012-12-26 2023-10-25 OncoSynergy, Inc. Anti-integrin-beta1-antikörperzusammensetzungen und verfahren zur verwendung davon
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
US10392629B2 (en) 2014-01-17 2019-08-27 Board Of Trustees Of Michigan State University Increased caloric and nutritional content of plant biomass
WO2015143228A1 (en) 2014-03-19 2015-09-24 The University Of North Carolina At Chapel Hill Bcl6 expression in eutopic endometrium as a marker for endometriosis and subfertility
MX2016012667A (es) 2014-03-28 2017-01-09 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
HUE055020T2 (hu) 2015-03-27 2021-11-29 Opko Diagnostics Llc Prosztata-antigén szabványok és azok felhasználása
JP6578119B2 (ja) * 2015-03-31 2019-09-18 株式会社Ｌｓｉメディエンス 前立腺特異抗原の測定方法及び測定キット
US11474105B2 (en) 2016-03-31 2022-10-18 The University Of North Carolina At Chapel Hill Methods and compositions for SIRT1 expression as a marker for endometriosis and subfertility
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7602422A (nl) * 1976-03-08 1977-09-12 Leuven Res & Dev Vzw Trombosetest.
US4849353A (en) * 1980-09-30 1989-07-18 Cornell Research Foundation, Inc. Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof
US4689323A (en) * 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
US5026653A (en) * 1985-04-02 1991-06-25 Leeco Diagnostic, Inc. Scavenger antibody mixture and its use for immunometric assay
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
SE8601645D0 (sv) * 1986-04-11 1986-04-11 Ulf R Nilsson Immunologiskt forfarande
US5114863A (en) * 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
US5223441A (en) * 1986-10-09 1993-06-29 Syntex (U.S.A.) Inc. Receptors for immune complexes
US5187067A (en) * 1986-12-15 1993-02-16 Teijin Limited Immunological determination of free human protein S and C4bp-protein S complex
EP0288793A3 (de) * 1987-04-22 1990-04-25 Abbott Laboratories Vorrichtung und Verfahren für die Ausführung eines festphasen Immunoassays
DE3727238A1 (de) * 1987-08-14 1989-02-23 Henning Berlin Gmbh Immunologisches bestimmungsverfahren zur bestimmung von hapteneigenschaften aufweisenden freien substanzen
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer

Also Published As

Publication number Publication date
US5599677A (en) 1997-02-04
AU1518795A (en) 1995-07-17
US5672480A (en) 1997-09-30
JPH09508969A (ja) 1997-09-09
ES2238678T3 (es) 2005-09-01
ATE290212T1 (de) 2005-03-15
JP2004093563A (ja) 2004-03-25
EP0741868B1 (de) 2005-03-02
WO1995018381A1 (en) 1995-07-06
DE69434286T2 (de) 2005-12-29
JP3486413B2 (ja) 2004-01-13
JP3833637B2 (ja) 2006-10-18
EP0741868A1 (de) 1996-11-13

Similar Documents

Publication Publication Date Title
DE69434286D1 (de) Immunologische bestimmungen von prostata-spezifischem antigen
ES8206856A1 (es) Mejoras en un metodo y su correspondiente equipo de ensayo para determinar antigenos por medio de una reaccion inmuno- quimica
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
NO830935L (no) Fremgangsmaate for fremstilling av nye konjugater som ved kovalent binding binder sammen et enzym og et antistoff
NO970292D0 (no) Bestemmelse av et spesifikt immunoglobulin ved anvendelse av multiple antigener
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
NO961151D0 (no) Antistoffer mot CD40
ES8706964A1 (es) Un procedimiento para fraccionar anticuerpos de suero.
KR850700111A (ko) 종양 및 비루스에 대하여 항-이디오 타입 항체로써 유도되는 면역반응
DE59509344D1 (de) Antikörperklassenspezifisches entstörungsreagenz
DE3854581D1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
DK0659276T3 (da) Immunoassay til eftervisning af collagen eller collagenfragmenter
ATE217086T1 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
DE3854999D1 (de) An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
ATE108907T1 (de) Bestimmungsverfahren, seine verwendung und komponenten.
CA2178504A1 (en) Immunoassays for prostate specific antigen
ES8609725A1 (es) Procedimiento para la determinacion de una sustancia capaz de fijarse inmunologicamente
Hoag et al. Optimal conditions for isolating human placental alkaline phosphatase by immunosorption
NO903820D0 (no) Fremgangsmaate for paavisning av analytter.
SE9500148D0 (sv) Antibodies for use in cancer therapy and diagnosis
AU1997897A (en) Nucleic acid-bound polypeptide, method of producing nucleic acid-bound polypeptide, and immunoassay using the polypeptide
CA2165672A1 (en) Antibodies specific for human prostate glandular kallikrein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition